Reported Earnings • Mar 30
Full year 2025 earnings released: EPS: €0.98 (vs €0.64 in FY 2024) Full year 2025 results: EPS: €0.98 (up from €0.64 in FY 2024). Revenue: €253.6m (up 8.7% from FY 2024). Net income: €16.7m (up 53% from FY 2024). Profit margin: 6.6% (up from 4.7% in FY 2024). The increase in margin was driven by higher revenue. Revenue is forecast to grow 6.1% p.a. on average during the next 3 years, compared to a 7.1% growth forecast for the Medical Equipment industry in Europe. Over the last 3 years on average, earnings per share has increased by 19% per year but the company’s share price has only increased by 5% per year, which means it is significantly lagging earnings growth. Declared Dividend • Feb 26
Dividend of €0.11 announced Shareholders will receive a dividend of €0.11. Ex-date: 10th March 2026 Payment date: 12th March 2026 Dividend yield will be 2.9%, which is higher than the industry average of 1.7%. Sustainability & Growth Dividend is covered by both earnings (55% earnings payout ratio) and cash flows (32% cash payout ratio). The dividend has decreased over the past 10 years, indicating a lack of growth and stability in payments. EPS is expected to grow by 44% over the next 3 years, which should provide support to the dividend and adequate earnings cover. Board Change • Jan 30
Less than half of directors are independent Following the recent departure of a director, there are only 5 independent directors on the board. The company's board is composed of: 5 independent directors. 7 non-independent directors. Independent Director María Rodríguez was the last independent director to join the board, commencing their role in 2025. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Declared Dividend • Dec 18
Dividend of €0.11 announced Shareholders will receive a dividend of €0.11. Ex-date: 19th December 2025 Payment date: 23rd December 2025 Dividend yield will be 2.8%, which is higher than the industry average of 1.7%. Sustainability & Growth Dividend is well covered by both earnings (40% earnings payout ratio) and cash flows (30% cash payout ratio). The dividend has decreased over the past 10 years, indicating a lack of growth and stability in payments. EPS is expected to grow by 44% over the next 3 years, which should provide support to the dividend and adequate earnings cover. Declared Dividend • Jul 07
Dividend of €0.19 announced Shareholders will receive a dividend of €0.19. Ex-date: 16th July 2025 Payment date: 18th July 2025 Dividend yield will be 3.1%, which is higher than the industry average of 1.7%. Sustainability & Growth Dividend is covered by both earnings (42% earnings payout ratio) and cash flows (71% cash payout ratio). The dividend has increased by an average of 8.3% per year over the past 10 years. However, payments have been volatile during that time. EPS is expected to grow by 56% over the next 3 years, which should provide support to the dividend and adequate earnings cover. Annuncio • May 28
Prim, S.A., Annual General Meeting, Jun 29, 2025 Prim, S.A., Annual General Meeting, Jun 29, 2025. Location: avenida del llano castellano 43, planta 3, fuencarral., madrid Spain New Risk • Apr 13
New major risk - Revenue size The company makes less than US$1m in revenue. This is considered a major risk. Companies with a small amount of revenue are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Revenue is less than US$1m. Minor Risk Paying a dividend despite having no free cash flows. Reported Earnings • Apr 04
Full year 2024 earnings released Full year 2024 results: Revenue: €235.0m (up 8.5% from FY 2023). Net income: €10.9m (down 14% from FY 2023). Profit margin: 4.6% (down from 5.9% in FY 2023). The decrease in margin was driven by higher expenses. Declared Dividend • Mar 03
Dividend of €0.089 announced Shareholders will receive a dividend of €0.089. Ex-date: 11th March 2025 Payment date: 13th March 2025 Dividend yield will be 3.5%, which is higher than the industry average of 1.7%. Sustainability & Growth Dividend is covered by earnings (67% earnings payout ratio) but the company has no free cash flows available, indicating it may be using cash reserves or debt to pay the dividend. The dividend has increased by an average of 8.3% per year over the past 10 years. However, payments have been volatile during that time. The company's earnings per share (EPS) would need to decline by 26% to shift the payout ratio to a potentially unsustainable range, which is more than the 1.5% EPS decline seen over the last 5 years. Reported Earnings • Sep 30
First half 2024 earnings released: EPS: €0.40 (vs €0.47 in 1H 2023) First half 2024 results: EPS: €0.40 (down from €0.47 in 1H 2023). Revenue: €119.7m (up 10% from 1H 2023). Net income: €6.77m (down 16% from 1H 2023). Profit margin: 5.7% (down from 7.4% in 1H 2023). Over the last 3 years on average, earnings per share has fallen by 11% per year whereas the company’s share price has fallen by 10% per year. Declared Dividend • Jul 08
Dividend of €0.18 announced Shareholders will receive a dividend of €0.18. Ex-date: 17th July 2024 Payment date: 19th July 2024 Dividend yield will be 3.4%, which is higher than the industry average of 1.7%. Sustainability & Growth Dividend is covered by earnings (36% earnings payout ratio) but the company has no free cash flows available, indicating it may be using cash reserves or debt to pay the dividend. The dividend has increased by an average of 5.7% per year over the past 10 years. However, payments have been volatile during that time. EPS is expected to remain steady over the next year, which should provide adequate earnings cover for the dividend. Buy Or Sell Opportunity • Jul 08
Now 23% overvalued after recent price rise Over the last 90 days, the stock has risen 6.5% to €10.50. The fair value is estimated to be €8.57, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 13% over the last 3 years, while earnings per share has been flat. Buy Or Sell Opportunity • Jun 04
Now 20% overvalued after recent price rise Over the last 90 days, the stock has risen 2.0% to €10.35. The fair value is estimated to be €8.62, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 13% over the last 3 years, while earnings per share has been flat. Declared Dividend • Mar 08
Dividend of €0.089 announced Shareholders will receive a dividend of €0.089. Ex-date: 13th March 2024 Payment date: 15th March 2024 Dividend yield will be 2.9%, which is higher than the industry average of 1.7%. Sustainability & Growth Dividend is covered by both earnings (64% earnings payout ratio) and cash flows (69% cash payout ratio). The dividend has increased by an average of 2.9% per year over the past 10 years. However, payments have been volatile during that time. EPS is expected to grow by 44% over the next year, which should provide support to the dividend and adequate earnings cover. New Risk • Feb 11
New major risk - Revenue and earnings growth Earnings have declined by 4.0% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 4.0% per year over the past 5 years. Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (4.7% net profit margin). New Risk • Oct 26
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Spanish stocks, typically moving 4.0% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 4.0% per year over the past 5 years. Minor Risks Dividend is not well covered by cash flows (98% cash payout ratio). Share price has been volatile over the past 3 months (4.0% average weekly change). Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (4.7% net profit margin). New Risk • Jun 30
New minor risk - Earnings quality The company has large one-off items impacting its financial results. One-off items were 29% of the size of the rest of the company's trailing 12-month earnings before tax. This is considered a minor risk. One-off items are incomes or expenses that the company does not expect to repeat in future periods. Examples include profits from the sale of a business or expenses from a restructuring or legal settlements. If the company's reported statutory earnings include a large proportion of one-off items it means they may be an unreliable indicator of its true business performance as the earnings were skewed by these incomes or expenses. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 3.0% per year over the past 5 years. Minor Risks Paying a dividend despite having no free cash flows. Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (4.3% net profit margin). Upcoming Dividend • Mar 06
Upcoming dividend of €0.089 per share at 4.6% yield Eligible shareholders must have bought the stock before 13 March 2023. Payment date: 16 March 2023. Payout ratio is a comfortable 47% but the company is not cash flow positive. Trailing yield: 4.6%. Lower than top quartile of Spanish dividend payers (6.1%). Higher than average of industry peers (1.8%). Reported Earnings • Mar 02
Full year 2022 earnings released: EPS: €0.50 (vs €1.01 in FY 2021) Full year 2022 results: EPS: €0.50 (down from €1.01 in FY 2021). Revenue: €197.2m (up 17% from FY 2021). Net income: €8.45m (down 52% from FY 2021). Profit margin: 4.3% (down from 10% in FY 2021). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 7.2% p.a. on average during the next 2 years, compared to a 6.4% growth forecast for the Medical Equipment industry in Europe. Over the last 3 years on average, earnings per share has increased by 8% per year but the company’s share price has remained flat, which means it is significantly lagging earnings. Upcoming Dividend • Dec 20
Upcoming dividend of €0.089 per share Eligible shareholders must have bought the stock before 27 December 2022. Payment date: 29 December 2022. Payout ratio is a comfortable 50% but the company is not cash flow positive. Trailing yield: 4.6%. Lower than top quartile of Spanish dividend payers (6.1%). Higher than average of industry peers (1.7%). Board Change • Nov 16
Less than half of directors are independent There are 8 new directors who have joined the board in the last 3 years. Of these new board members, 3 were independent directors. The company's board is composed of: 8 new directors. 2 experienced directors. No highly experienced directors. 4 independent directors (6 non-independent directors). Independent Director Maria Belen Amatriain Corbi is the most experienced director on the board, commencing their role in 2015. Independent Director Mar Mateo was the last independent director to join the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors. Board Change • Apr 27
Less than half of directors are independent There are 5 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 3 independent directors. 6 non-independent directors. Independent Director Maria Belen Amatriain Corbi was the last independent director to join the board, commencing their role in 2015. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Upcoming Dividend • Mar 02
Upcoming dividend of €0.089 per share Eligible shareholders must have bought the stock before 09 March 2022. Payment date: 11 March 2022. Payout ratio is a comfortable 31% and this is well supported by cash flows. Trailing yield: 2.2%. Lower than top quartile of Spanish dividend payers (5.6%). Higher than average of industry peers (1.2%). Reported Earnings • Feb 27
Full year 2021 earnings: Revenues and EPS in line with analyst expectations Full year 2021 results: EPS: €1.01 (up from €0.40 in FY 2020). Revenue: €168.5m (up 14% from FY 2020). Net income: €17.4m (up 152% from FY 2020). Profit margin: 10% (up from 4.7% in FY 2020). The increase in margin was driven by higher revenue. Revenue was in line with analyst estimates. Over the next year, revenue is forecast to grow 15%, compared to a 17% growth forecast for the industry in Spain. Over the last 3 years on average, earnings per share has increased by 3% per year whereas the company’s share price has increased by 8% per year. Upcoming Dividend • Dec 08
Upcoming dividend of €0.089 per share Eligible shareholders must have bought the stock before 14 December 2021. Payment date: 16 December 2021. Payout ratio is a comfortable 39% and this is well supported by cash flows. Trailing yield: 2.2%. Lower than top quartile of Spanish dividend payers (5.4%). Higher than average of industry peers (1.0%). Reported Earnings • Aug 04
Second quarter 2021 earnings released: EPS €0.27 (vs €0.059 in 2Q 2020) The company reported a strong second quarter result with improved earnings, revenues and profit margins. Second quarter 2021 results: Revenue: €44.5m (up 51% from 2Q 2020). Net income: €4.54m (up 338% from 2Q 2020). Profit margin: 10% (up from 3.5% in 2Q 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 12% per year but the company’s share price has increased by 3% per year, which means it is well ahead of earnings. Reported Earnings • Apr 28
Full year 2020 earnings released: EPS €0.40 (vs €0.65 in FY 2019) The company reported a poor full year result with weaker earnings, revenues and profit margins. Full year 2020 results: Revenue: €147.3m (down 2.4% from FY 2019). Net income: €6.92m (down 38% from FY 2019). Profit margin: 4.7% (down from 7.4% in FY 2019). Over the last 3 years on average, earnings per share has fallen by 18% per year but the company’s share price has only fallen by 5% per year, which means it has not declined as severely as earnings. Reported Earnings • Mar 02
Full year 2020 earnings released The company reported a poor full year result with weaker earnings, revenues and profit margins. Full year 2020 results: Revenue: €147.3m (down 2.4% from FY 2019). Net income: €6.92m (down 38% from FY 2019). Profit margin: 4.7% (down from 7.4% in FY 2019). Over the last 3 years on average, earnings per share has fallen by 14% per year but the company’s share price has only fallen by 1% per year, which means it has not declined as severely as earnings. Is New 90 Day High Low • Feb 25
New 90-day high: €10.60 The company is up 15% from its price of €9.20 on 27 November 2020. The Spanish market is up 1.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Medical Equipment industry, which is up 11% over the same period. Is New 90 Day High Low • Feb 06
New 90-day high: €9.94 The company is up 10.0% from its price of €9.04 on 06 November 2020. The Spanish market is up 16% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Medical Equipment industry, which is up 13% over the same period. Is New 90 Day High Low • Dec 31
New 90-day high: €9.70 The company is up 7.0% from its price of €9.10 on 02 October 2020. The Spanish market is up 18% over the last 90 days, indicating the company underperformed over that time. However, its price trend is similar to the Medical Equipment industry, which is also up 7.0% over the same period. Reported Earnings • Nov 16
Third quarter 2020 earnings released: EPS €0.15 The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2020 results: Revenue: €37.0m (up 11% from 3Q 2019). Net income: €2.58m (up 87% from 3Q 2019). Profit margin: 7.0% (up from 4.1% in 3Q 2019). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 13% per year but the company’s share price has only fallen by 2% per year, which means it has not declined as severely as earnings. Is New 90 Day High Low • Nov 12
New 90-day high: €9.68 The company is up 5.0% from its price of €9.18 on 14 August 2020. The Spanish market is up 7.0% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Medical Equipment industry, which is up 2.0% over the same period. Is New 90 Day High Low • Oct 19
New 90-day low: €8.86 The company is down 11% from its price of €9.90 on 21 July 2020. The Spanish market is down 6.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Medical Equipment industry, which is flat over the same period.